{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["CCl(4)", "JAK2/STAT3", "Liver fibrosis", "Lycorine", "PI3K/AKT"]], "OtherAbstract": [], "SpaceFlightMission": [], "InvestigatorList": [], "CitationSubset": ["IM"], "OtherID": [], "GeneralNote": [], "PMID": "38925513", "DateCompleted": {"Year": "2024", "Month": "07", "Day": "11"}, "DateRevised": {"Year": "2024", "Month": "08", "Day": "07"}, "Article": {"Language": ["eng"], "ELocationID": ["10.1016/j.taap.2024.117017", "S0041-008X(24)00215-1"], "ArticleDate": [{"Year": "2024", "Month": "06", "Day": "24"}], "Journal": {"ISSN": "1096-0333", "JournalIssue": {"Volume": "489", "PubDate": {"Year": "2024", "Month": "Aug"}}, "Title": "Toxicology and applied pharmacology", "ISOAbbreviation": "Toxicol Appl Pharmacol"}, "ArticleTitle": "Lycorine relieves the CCl<sub>4</sub>-induced liver fibrosis mainly via the JAK2/STAT3 and PI3K/AKT signaling pathways.", "Pagination": {"StartPage": "117017", "MedlinePgn": "117017"}, "Abstract": {"AbstractText": ["Liver fibrosis, a progressive process of fibrous scarring, results from the accumulation of extracellular matrix proteins (ECM). If left untreated, it often progresses to diseases such as cirrhosis and hepatocellular carcinoma. Lycorine, a natural alkaloid derived from medicinal plants, has shown diverse bioactivities by targeting JAK2/STAT3 signaling, but its pharmacological effects and potential molecular mechanisms in liver fibrosis remains largely unexplored. The purpose of this study is to elucidate the pharmacological activity and molecular mechanism of lycorine in anti-hepatic fibrosis. Findings indicate that lycorine significantly inhibited hepatic stellate cells (HSCs) activation by reducing the expression of \u03b1-SMA and collagen-1. In vivo, lycorine treatment alleviated carbon tetrachloride (CCl<sub>4</sub>) -induced mice liver fibrosis, improving liver function, decreasing ECM deposition, and inhibiting fibrosis-related markers' expression. Mechanistically, it was found that lycorine exerts protective activity through the JAK2/STAT3 and PI3K/AKT signaling pathways, as evidenced by transcriptome sequencing technology and small molecule inhibitors. These results underscore lycorine's potential as a therapeutic drug for liver fibrosis."], "CopyrightInformation": "Copyright \u00a9 2024 Elsevier Inc. All rights reserved."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Affiliated Yueqing Hospital, Wenzhou Medical University, Wenzhou, Zhejiang 325600, China; Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China."}], "LastName": "Tang", "ForeName": "Yue", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medicine Care Center, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325035, China. Electronic address: zhuzaisheng@wmu.edu.cn."}], "LastName": "Zhu", "ForeName": "Zaisheng", "Initials": "Z"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China."}], "LastName": "Li", "ForeName": "Mengying", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China."}], "LastName": "Gao", "ForeName": "Lijiao", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China."}], "LastName": "Wu", "ForeName": "Xinyi", "Initials": "X"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China."}], "LastName": "Chen", "ForeName": "Jingyi", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Affiliated Yueqing Hospital, Wenzhou Medical University, Wenzhou, Zhejiang 325600, China; Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China. Electronic address: ya-li000@163.com."}], "LastName": "Zhang", "ForeName": "Yali", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Life Sciences, Biomedical Collaborative Innovation Center of Zhejiang Province, Wenzhou University, Wenzhou, Zhejiang 325035, China. Electronic address: haiyangwzu@163.com."}], "LastName": "Zhao", "ForeName": "Haiyang", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Affiliated Yueqing Hospital, Wenzhou Medical University, Wenzhou, Zhejiang 325600, China. Electronic address: xiangzi198155@163.com."}], "LastName": "Xiao", "ForeName": "Zhongxiang", "Initials": "Z"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "Toxicol Appl Pharmacol", "NlmUniqueID": "0416575", "ISSNLinking": "0041-008X"}, "ChemicalList": [{"RegistryNumber": "EC 2.7.10.2", "NameOfSubstance": "Janus Kinase 2"}, {"RegistryNumber": "0", "NameOfSubstance": "STAT3 Transcription Factor"}, {"RegistryNumber": "I9Q105R5BU", "NameOfSubstance": "lycorine"}, {"RegistryNumber": "0", "NameOfSubstance": "Amaryllidaceae Alkaloids"}, {"RegistryNumber": "CL2T97X0V0", "NameOfSubstance": "Carbon Tetrachloride"}, {"RegistryNumber": "EC 2.7.11.1", "NameOfSubstance": "Proto-Oncogene Proteins c-akt"}, {"RegistryNumber": "EC 2.7.10.2", "NameOfSubstance": "Jak2 protein, mouse"}, {"RegistryNumber": "0", "NameOfSubstance": "Stat3 protein, mouse"}, {"RegistryNumber": "0", "NameOfSubstance": "Phenanthridines"}, {"RegistryNumber": "EC 2.7.1.-", "NameOfSubstance": "Phosphatidylinositol 3-Kinases"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["metabolism"], "DescriptorName": "Janus Kinase 2"}, {"QualifierName": ["metabolism"], "DescriptorName": "STAT3 Transcription Factor"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Amaryllidaceae Alkaloids"}, {"QualifierName": ["toxicity"], "DescriptorName": "Carbon Tetrachloride"}, {"QualifierName": ["drug effects"], "DescriptorName": "Signal Transduction"}, {"QualifierName": ["metabolism"], "DescriptorName": "Proto-Oncogene Proteins c-akt"}, {"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": ["drug effects", "metabolism", "pathology"], "DescriptorName": "Hepatic Stellate Cells"}, {"QualifierName": ["drug therapy", "chemically induced", "pathology", "metabolism"], "DescriptorName": "Liver Cirrhosis"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Phenanthridines"}, {"QualifierName": ["metabolism"], "DescriptorName": "Phosphatidylinositol 3-Kinases"}, {"QualifierName": [], "DescriptorName": "Mice, Inbred C57BL"}, {"QualifierName": [], "DescriptorName": "Cell Line"}], "CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper."}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2024", "Month": "2", "Day": "1"}, {"Year": "2024", "Month": "6", "Day": "21"}, {"Year": "2024", "Month": "6", "Day": "22"}, {"Year": "2024", "Month": "7", "Day": "12", "Hour": "0", "Minute": "41"}, {"Year": "2024", "Month": "6", "Day": "27", "Hour": "0", "Minute": "42"}, {"Year": "2024", "Month": "6", "Day": "26", "Hour": "19", "Minute": "29"}], "PublicationStatus": "ppublish", "ArticleIdList": ["38925513", "10.1016/j.taap.2024.117017", "S0041-008X(24)00215-1"]}}]}